Development of VISTA in tumor immunotherapy / 中国药科大学学报
Journal of China Pharmaceutical University
; (6): 400-409, 2022.
Article
in Zh
| WPRIM
| ID: wpr-939965
Responsible library:
WPRO
ABSTRACT
@#V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a member of the B7 family that maintains homeostasis in T cells and myeloid cells.Blocking VISTA inhibits tumor development in in vitro and in vivo trials, and is an important target for tumor immunotherapy.This review focuses on its structural features, expression and biological functions in tumor microenvironment, summarizes the current stage of small molecule inhibitors and antibodies targeting VISTA, and discusses the research approaches.It aims to provide a rationale for subsequent study on VISTA and the development of related immune checkpoint antitumor drugs.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Journal of China Pharmaceutical University
Year:
2022
Document type:
Article